Léčba pokročilého nemalobuněčného karcinomu plic (NSCLC) v ČR v roce 2017 (aktuální stav, výhled do budoucna)
Title in English | Treatment of non-small cell lung cancer (NSCLC) in the Czech Republic in 2017 |
---|---|
Authors | |
Year of publication | 2017 |
Type | Conference abstract |
MU Faculty or unit | |
Citation | |
Description | The prospects of NSCLC patients have improved considerably since the advent of biological treatment (tyrosin kinase inhibitors such as erlotinib, gefinitib and afatinib) and immunotherapy . Thanks to these treatment modalities, the survival of NSCLC patients improved significantly, as data from the TULUNG registry show. |